Abstract
Clinical investigation of DL-8280, a new synthetic antimicrobial agent of oxazine derivative, was performed.
Eleven inpatients and 1 outpatient entered into this study. Eleven patients were suffered from urinary tract infections (cystitis, 6 patients ; pyelonephritis, 5 patients) and the remaining 1 patient was suffered from chronic bronchitis.
Causative pathogens isolated from urinary tract infections were E. coli 2 cases, S. marcescens 2 cases, S. faecalis 2 cases, P. aeruginosa 1 case, P mirabilis 1 case, P. morganii 1 case and S. epidermidis 1 case.H. influenzae was isolated from the patient of chronic bronchitis.
DL-8280 was administered orally twice or three times a day. The daily does ranged from 200 to 600 mg and the administration period was 3 to 15 days.
Clinical efficacy on urinary tract infections was “marked” in 3, “effective” in 4, “slightly effective” in 2 and “failure” in 2 and in chronic bronchitis “effective” was observed as a result.
Neither side effect nor abnormal change in laboratory test value was observed.
